51934-39-5

Usage

Uses

Used in Chemical Synthesis:
7-Bromonaphthalene-1-carboxylic acid is used as a precursor in the synthesis of various organic compounds for [application reason]. Its unique structure, featuring a naphthalene ring with a bromine atom and a carboxylic acid group, makes it a versatile building block in organic chemistry.
Used in Laboratory Research:
7-Bromonaphthalene-1-carboxylic acid is used as a reagent in laboratory settings for conducting various chemical reactions and experiments. Its properties allow researchers to explore its potential applications and reactions with other compounds.
Used in Pharmaceutical Industry:
7-Bromonaphthalene-1-carboxylic acid is used as an intermediate in the development of pharmaceutical compounds for [application reason]. Its chemical structure may contribute to the creation of new drugs with specific therapeutic properties.
Used in Chemical Formulation:
7-Bromonaphthalene-1-carboxylic acid is used as a component in the formulation of various chemical products for [application reason]. Its presence in these formulations can enhance their performance or provide specific functional benefits.

InChI:InChI=1/C11H7BrO2/c12-8-5-4-7-2-1-3-9(11(13)14)10(7)6-8/h1-6H,(H,13,14)

Upstream product

• 33295-35-1 2-bromo-8-methylnaphthalene 
• 32281-97-3 7-bromo-3,4-dihydro-2H-naphthalen-1-one 
• 35943-87-4 7-bromo-1-methyl-3,4-dihydronaphthalene 
• 1590-24-5 (7-bromo-1-naphthalenyl)ethanone 
• 580-13-2 2-bromonaphthalene 
• 35656-89-4 4-(4-bromophenyl)butanoic acid 

Downstream Products

• 319-04-0 7-Bromo-1-fluoronaphthalene 
• 3109-50-0 o-(<8-Fluor-2-naphthyl>-methyl)-benzoesaeure 
• 2965-43-7 2-(8-Fluor-naphthoyl)-benzoesaeure 
• 93353-67-4 7-bromo-1-naphthoic acid methyl ester 

Relevant academic research and scientific papers

Novel, Self-Assembling Dimeric Inhibitors of Human β Tryptase

β-Tryptase, a homotetrameric serine protease, has four identical active sites facing a central pore, presenting an optimized setting for the rational design of bivalent inhibitors that bridge two adjacent sites. Using diol, hydroxymethyl phenols or benzoyl methyl hydroxamates, and boronic acid chemistries to reversibly join two [3-(1-acylpiperidin-4-yl)phenyl]methanamine core ligands, we have successfully produced a series of self-assembling heterodimeric inhibitors. These heterodimeric tryptase inhibitors demonstrate superior activity compared to monomeric modes of inhibition. X-ray crystallography validated the dimeric mechanism of inhibition, and compounds demonstrated high selectivity against related proteases, good target engagement, and tryptase inhibition in HMC1 xenograft models. Screening 3872 possible combinations from 44 boronic acid and 88 diol derivatives revealed several combinations that produced nanomolar inhibition, and seven unique pairs produced greater than 100-fold improvement in potency over monomeric inhibition. These heterodimeric tryptase inhibitors demonstrate the power of target-driven combinatorial chemistry to deliver bivalent drugs in a small molecule form.

FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS

In its many embodiments, the present invention provides a novel class of naphthene- and indane-type as inhibitors of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.

N-(Naphthalenylthioxomethyl)aminoacid derivatives

Herein disclosed are N-(naphthalenylthioxomethyl)aminoacid derivatives having aldose reductase inhibiting activity. The derivatives are useful for treating diabetic complications.